Verici Logo

News

Notice of Results

September 6, 2021
Verici Dx announces that it will release its unaudited results for the six-month period to 30 June 2021 on Monday 13 September 2021.
Keep Reading

Patient enrolment completed for clinical validation trial for lead products ClaravaTM and TutevaTM

August 31, 2021
Verici Dx remains on track for completion of study end points by the end of 2021 for lead products
Keep Reading

Appointment of Non-executive Director

August 19, 2021
Verici Dx plc announces the appointment to the Board of Lorenzo Gallon, MD, as Non-executive Director with immediate effect.
Keep Reading

Acceptance to CLIA Program

July 27, 2021
Major milestone in the commercial launch of Verici Dx’s lead products, ClaravaTM and TutevaTM
Keep Reading

Verici expands its clinical trial by opening first site in Europe

July 20, 2021
Multi-centre validation trial for leading products on track for completion by the end of the year including participation from European sites.   Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has initiated its first European clinical validation trial site with Prof. Gaetano La Manna, Director of […]
Keep Reading

Death of Director

July 1, 2021
The Board of Verici Dx plc (AIM: VRCI), is saddened to announce the death of Dr. Barbara Murphy, Non-Executive Director, who passed away on June 29, 2021. Dr. Murphy had continued to fully discharge her duties as a Director through a recent period of illness, however over the past few weeks her health deteriorated. Dr. Murphy joined the Board […]
Keep Reading

Notice of Change of AGM Venue

May 5, 2021
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces a change in venue of its Annual General Meeting (‘AGM’), which will now take place at Harwood Capital, 6 Stratton Street, Mayfair, W1J 8LD on 19 May 2021 at 12.00pm.   As previously announced, the Company is providing a facility […]
Keep Reading

Lease signed for laboratory as part of CLIA approval acceleration strategy

April 29, 2021
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has signed the lease for the premises intended to be the CLIA1-certified laboratory, situated at the Innovation Park2 in Franklin, Tennessee, US, which is within the Palmetto region for CMS Medicare governance. Palmetto GBA, LLC is one of the […]
Keep Reading

Material Transfer Agreement secured to assess CTOT-19 samples using Clarava™ and Tuteva™

April 14, 2021
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has entered into a Material Transfer Agreement (“MTA”) with the Icahn School of Medicine at Mount Sinai and Principal Investigator Dr. Peter Heeger, to allow access to samples from the CTOT-19 (Clinical Trials in Organ Transplant1) trial in an […]
Keep Reading

Final Results for the period ended 31 December 2020

April 14, 2021
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces its inaugural audited results for the period ended 31 December 2020.   Strategic and Operational highlights Verici Dx was successfully admitted to AIM in November raising gross proceeds of c.$18.8m (£14.5m) The fundraising was significantly oversubscribed by institutional and other […]
Keep Reading
crossmenu